These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 19027221)
1. Editorial comment on: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Novara G Eur Urol; 2009 Apr; 55(4):873-4. PubMed ID: 19027221 [No Abstract] [Full Text] [Related]
2. Editorial comment on: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Ahyai SA; Schlomm T Eur Urol; 2009 Apr; 55(4):874-5. PubMed ID: 19027220 [No Abstract] [Full Text] [Related]
3. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Alcaraz A; Hammerer P; Tubaro A; Schröder FH; Castro R Eur Urol; 2009 Apr; 55(4):864-73. PubMed ID: 19027219 [TBL] [Abstract][Full Text] [Related]
5. [Dyshormonal hyperplasia of the prostate gland and cancer]. Griunval'd-Agafdnova DL Vopr Onkol; 1969; 15(5):54-9. PubMed ID: 4188197 [No Abstract] [Full Text] [Related]
6. [Sexual problems in patients with prostate cancer and those with benign prostatic hypertrophy]. Danilin JE; Marilov VV; Brukhin AE Rev Med Suisse; 2011 Mar; 7(287):648, 650-2. PubMed ID: 21542379 [TBL] [Abstract][Full Text] [Related]
7. Editorial comment on: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Novara G Eur Urol; 2008 Oct; 54(4):775-6. PubMed ID: 18571305 [No Abstract] [Full Text] [Related]
8. Editorial comment on: Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Gratzke C; Reich O Eur Urol; 2008 Oct; 54(4):776-7. PubMed ID: 18571304 [No Abstract] [Full Text] [Related]
10. [Neuroendocrine cells in the morphogenesis of prostatic pathology]. Algaba F; Trias I Arch Esp Urol; 1995 Apr; 48(3):217-22. PubMed ID: 7538748 [No Abstract] [Full Text] [Related]
11. Editorial comment on: Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Seitz M; Gratzke C Eur Urol; 2009 Mar; 55(3):591. PubMed ID: 18952366 [No Abstract] [Full Text] [Related]
12. [Pathomorphologic and pathogenetic study on 281 cases of prostatic hyperplasia]. Luo AT Zhonghua Yi Xue Za Zhi; 1983 Feb; 63(2):101-3. PubMed ID: 6190540 [No Abstract] [Full Text] [Related]
13. [Treatment of cancer of the prostate]. Vernet SG Ann Urol (Paris); 1970 Feb; 4(1):9-16. PubMed ID: 4194186 [No Abstract] [Full Text] [Related]
14. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074 [TBL] [Abstract][Full Text] [Related]
15. Editorial: Benign hyperplasia and cancer of the prostate. Br Med J; 1975 Jan; 1(5948):2-3. PubMed ID: 47254 [No Abstract] [Full Text] [Related]
16. The management of category T1a-T1b (incidental) prostate cancer: can we predict who needs treatment? Adolfsson J Eur Urol; 2008 Jul; 54(1):16-8. PubMed ID: 18406047 [No Abstract] [Full Text] [Related]